10-29-97

Docket No: GI 5358 CIP

CIP ent #7/166

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Jacobs, et al

Serial No.:

10/084,298

Group Art No.:

1614

Filed: For:

February 25, 2002

Examiner:

COMPOSITION AND METHOD FOR TREATING

INFLAMMATORY DISORDERS

Confirmation No.:

7985

Customer Number:

25291

Assistant Commissioner for Patents

Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL 953853535 US addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

10/28/02

Date

Kerry A. McCarthy

Patent

2.	Iden	tification of Time of Filing
	This	Information Disclosure Statement
	a.	is filed within three months of the filing date of the application.
	b.	is filed before the mailing date of a first Office Action on the merits.
	c.	is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
	d.	is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
	e.	is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).
3.		Certification under 37 CFR 1.97(e) and 1.704(d) The undersigned attorney certifies
	a.	that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
	b.	that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
	c.	The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.
	\boxtimes	Newly Cited Information A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed.
		Previously Cited Information No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.
		Prior application is Serial Number , filed on of for .

Docket No: GI 5358 CIP Patent

	Conc	ise Explanation
	Docu	ments cited above which are not in the English Language
a.	Щ	have been explained in the specification.
b.	Ш	have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.
Form	PTO-	1449 is enclosed in duplicate.
	Fees	
		Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00
		Payment of Fees:
	-	posit Account No. 07-1060 in the amount of \$0.00
A du	рисац	of this statement is enclosed.
		s as to Overpayment/Underpayment:
Credi	it any	overpayment and charge any underpayment to Deposit Account No. 07-1060.
		Diane Callas
		Diana M. Collazo

Reg. No. 46,635

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (617) 665-8775

			E		
C. Larie et S. C. 1440 mmo		Co	mplete if Known 🏏	, 6, C	
Substitute for form 1449/PTO		Application Number	10/084,298		
INFORMATION DISCLOSURE		Filing Date	February 25, 2002	12 / Z	
STATEMENT BY APPLICANT		First Named Inventor	Jacobs, et al	50 20	<u>त</u>
OCT 2 8 2000 se as many sheets as necessar	v)	Group Art Unit	1614	00 00	8
And the same of th		Examiner Name		0	0
Deet 1 of	2	Attorney Docket Number	GI 5358 CIP	(A)	
A LOCAL AND A LOCA				8	
WADE	U.S. P	ATENT DOCUMENTS			

I ARA	DEW			U.S. PATENT DOCUM	MENTS	
Examiner Initials*	Cite No.	U.S. Patent Docu Number (If known)	Kind Code (If Known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	5,350,836-A		Kipchick et al	09-1994	
	2.	5,536,637		Jacobs	07-1996	
	3.	6,359,117		Dumoutier et al	07-16-1999	
	4.	6,331,613		Dumoutier et al	10-18-1999	
7	5.	6,274,710		Dumoutier et al	10-26-1998	
	6.	US2001/0024652		Ludwig Institute for Cancer	09-27-2001	
		A1		Research		

			F	OREIGN P	PATENT DOCUMENTS			
Examiner Initials*	Cite No.		Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office	Number	Kind Code (If Known)	Applicant of Cited document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т
	7.		WO 94/01548-A2		Sibson, et al	01-1994	1	
	8.		WO 01/46422 A1		Zymogenetics, Inc.	06-28-2001	•	
	9.		WO 00/77037 A2		Genentech, Inc.	12-21-2000		
	10.		WO 00/73457 A1		Schering-Corporation	12-07-2000	1,	
	11.		WO 00/70049		Incyte Genomics, Inc.	11-23-2000		
	12.		WO 99/61617		Human Genome Sciences, Inc.	12-02-1999		
	13.		WO 00/24758		Ludwig Institute for Cancer Research	05-04-2000		
	14.		WO 02/10393 A2		Ludwig Institute for Cancer Research	02-07-2002		

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	15.	Mahairas G., et al. Database EST. Accession No. AQ104025. 28 Aug 1998.	
	16.	Waterston R., et al. Database GenEmbl. Accession No. AC006734. 25 Feb 1999.	
	17.	Wilson R., et al. J. Mol. Biol. 261:155-172, 1996.	
	18.	Bork, et al. Trends in Genetics 12:425-427, 1996.	
	19.	Vukicevic, et al. PNAS USA 93:9021-9026, 1996.	
	20.	Massague J. Cell 49:437-8, 1987.	
•	21.	Pilbeam, et al. Bone 14:717-720, 1993.	
	22.	Skolnick, et al. Trends in Biotech. 18:34-39, 2000.	
	23.	Dumoutier, et al. (2000), "Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9," J. of Immunol. 164:1814-1819.	
	24.	<u> </u>	
	25.	Dumoutier, L., et al. GenBank Accession number NM_016971 for mus musculus interleukin 10-related T cell-derived inducible factor (Iltif). 08 Jun 2000.	
	26.	Aoki, I., et al. "Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins," FEBS Lett. 282(1):56-60, 1991.	
	27.	Dumoutier, L., et al., "Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor," PNAS 97(18):10144-9, 2000.	
	28.		
	29.	Ozaki, T., et al. GenBank Accession number D13973 for Dictyostelium discoideum DNA for Dp87 protein, 1993. 01 Feb 2000.	

Examiner	Date	
Signature	Consi	dered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		omplete if Known
OIR	Application Number	10/084,298
INFORMATION DISCLOSURE	Filing Date	February 25, 2002
TATEMENT BY APPLICANT	First Named Inventor	Jacobs, et al
(use as many sheets as necessary)	Group Art Unit	1614
E ALL T	Examiner Name	
2 of 2	Attorney Docket Number	GI 5358 CIP

TADE	MARK	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or publisher.	Т
	30.	Aoki, I., et al. GenBank Accession Number P35709 for Eosinophil granule major basic protein 2 percursor (mbp-2). 30 May 2000.	
	31.	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	+-
	32.	Dumoutier, L., et al. GenBank Accession Number AJ294727 for Mus musculus ILTIFa gene for IL TIE alpha protein (IL-21), exons 1a 5. 21 Dec 2000.	
	33.	Dumoutier, L., et al. GenBank Accession Number NP_065386 for Interleukin 22; interleukin 21; IL-10-related T-cell-derived inducible factor (homo sapiens). 02 Nov 2000.	
	34.	Ozaki, T., et al., "Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictyostelium discoideum," Development. 117(4):1299-308, 1993.	
	35.	Sambrook, J., et al. Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.	
	36.	Xie, M.H., et al., "Interleukin IL-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R," J. Biol. Chem. 275(40):31335-9, 2000.	



S:\LACOMMON\PATENTS\AMEND\5358\CIP\PTO 1449.doc

Examiner	Date	
0:	Date	l l
Signature	Considered	I I
	 Considered	<u></u>

_,	•		4							RECEI OCT 3 1 20	
								Com	plete if Known	CEA	-
Subottista	form	1449/PTC)			-	Application Nun	nber	10/084,298 February 25, 200 Jacobs, et al	OCT	<u> </u>
300 T	, A			_			Filing Date		February 25, 200	31 20	18.
/	٠ <u>٠</u>	INFORMAT	TION DISCL NT BY APPL	OSURE			First Named Inv	entor	Jacobs, et al	WIT CENTER CU	<u>U2</u>
ດຕາ							Group Art Unit		1614	- 1600	_ _
2 061- 2	• AUZ (ug	e as many	sheets as r	necessary)		ŀ	Examiner Name			, 999/	2900
		?/	1	of		2	Attorney Docker	t Number	GI 5358 CIP		
Theet	CHAPT C			01 1							
					ι	J.S. PAT	ENT DOCUM	ENTS	Pa	ges, Columns, Lines,	
	1	U.S. Patent Document				Niama of Pater	tee or Applicant	Date of Publicati	on of	Where Relevant	
Examiner	Cite No.	Nun	ber	Kind Code	•		Document	Cited Docume MM-DD-YY		assages or Relevant Figures Appear	
Initials*	No.	(If kn	own)	(If Known)				09-1994			
	1.	5,350,83	6-A			chick et al		07-1996			
	2.	5,536,63	7		Jaco		1	07-16-1999	-		
	3.	6,359,11	7			noutier et a		10-18-1999			
	4.	6,331,61		<u> </u>		noutier et		10-26-1998			
	5.	6,274,71			Dun	noutier et	al Concer	09-27-2001			
	6.		/0024652	ļ			ate for Cancer	0)-27-2001	į		
l	<u> </u>	A1		J	Res	earch					
					FOI	PEICNE	PATENT DOC	UMENTS			
						CETOIT	1		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner	Cite		Foreign	Patent Docur	nent	1 10.1	Name of Par Applicant of Cit		Cited Document	Passages or Relevant	T
Initials*	No.	Office	}	Number		(If Known)	Applicant of Cit	ed document	MM-DD-YYYY	Figures Appear	╀╼┤
<u> </u>	 		WO 04/	01548-A2			Sibson, et al		01-1994		┼┶┵┤
ļ	7.	 -		46422 A1			Zymogenetics,	Inc.	06-28-2001	<u> </u>	+-+
ļ	8.	 		77037 A2			Genentech, Inc		12-21-2000		4
	9.	 		73457 A1		<u> </u>	Schering-Corp		12-07-2000		
	11.		WO 00/				Incyte Genomi	cs, Inc.	11-23-2000		+
 	11.	+	WO 99/			1	Human Genom	ne Sciences,	12-02-1999		
	12.		""	0.00.			Inc.		25.04.2000		+
	13.	 	WO 00/	24758			Ludwig Institu	te for Cancer	05-04-2000		

The prior of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 15. Mahairas G., et al. Database EST. Accession No. AQ104025. 28 Aug 1998. 16. Waterston R., et al. Database GenEmbl. Accession No. AC006734. 25 Feb 1999. 17. Wilson R., et al. J. Mol. Biol. 261:155-172, 1996. 18. Bork, et al. Trends in Genetics 12:425-427, 1996. 19. Vukicevic, et al. PNAS USA 93:9021-9026, 1996. 20. Massague J. Cell 49:437-8, 1987.	1										
Examiner Initials* Cite No. Include name of the author (in CAPITAL LETTERS), till of the author (in CAPITAL LETTERS),											
Examiner Initials* Cite No. Include name of the author (in CAPITAL LETTERS), fill of the author (in CAPITAL LETTERS), and the author (in CAPITAL LETTER											
Cite Item (book, magazine, journal, serial, symposium, catalog, etc.) tate, page 57, votation Publisher, city and/or country where published.											
No. Publisher, city and/or county where publisher. City and Ci											
16. Waterston R., et al. Database GenEmbl. Accession No. AC006/34. 23 Teb 1995. 17. Wilson R., et al. J. Mol. Biol. 261:155-172, 1996. 18. Bork, et al. Trends in Genetics 12:425-427, 1996. 19. Vukicevic, et al. PNAS USA 93:9021-9026, 1996. 20. Massague J. Cell 49:437-8, 1987.											
17. Wilson R., et al. J. Mol. Biol. 261:155-172, 1996. 18. Bork, et al. Trends in Genetics 12:425-427, 1996. 19. Vukicevic, et al. PNAS USA 93:9021-9026, 1996. 20. Massague J. Cell 49:437-8, 1987.											
18. Bork, et al. Trends in Genetics 12:425-427, 1996. 19. Vukicevic, et al. PNAS USA 93:9021-9026, 1996. 20. Massague J. Cell 49:437-8, 1987.	Waterston R., et al. Database GenEmbl. Accession No. AC000734, 23 Teb 1999.										
19. Vukicevic, et al. PNAS USA 93:9021-9026, 1996. 20. Massague J. Cell 49:437-8, 1987.	Wilson R., et al. J. Mol. Biol. 261:155-172, 1996.										
19. Vukicevic, et al. PNAS USA 93:9021-9026, 1996. 20. Massague J. Cell 49:437-8, 1987.	\top										
20 Massague J. Cell 49:437-8, 1987.	Vukicevic, et al. PNAS USA 93:9021-9026, 1996.										
	Massague J. Cell 49:437-8, 1987.										
21. Pilbeam, et al. Bone 14:717-720, 1993.	Pilheam et al. Bone 14:717-720, 1993.										
grue a navel outokine structurally related to IL-10 and inductore by iL-5, 5. 61 minutes	十										
	寸										
25 Dumoutier, L., et al. GenBank Accession number NW_010971 for hids museums interest and property of the second states are second states and property of the second states and property of the second states and property of the second states are second states and property of the second states are second states and property of the second states are second states and the second states are second states are second states and the second states are se											
	1										
26 Acki L et al "Comparison of the amino acid and nucleotide sequences between normal and the game I											
	_										
1 WIT interded in Cell-Reflyed inductive interded	1										
	es										
functional characterization as an hepatocyte-stimulating factor, Trans 3 (25) 28. Dumoutier, L., et al., "IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes," Gen	-										
	_										
Immun. 1:488-494, 2000. 29. Ozaki, T., et al. GenBank Accession number D13973 for Dictyostelium discoideum DNA for Dp87 protein,											
1993. 01 Feb 2000.	l										

Research

Ludwig Institute for Cancer

02-07-2002

13.

Examiner

WO 02/10393 A2

Date

Considered

Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Known
298
y 25, 2002
et al
CIP

	DEMIOA	OTHER PRIOR ART — NON PATENT ELLERATORE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	30.	Aoki, I., et al. GenBank Accession Number P35709 for Eosinophil granule major basic protein 2 percursor	
		(mbp-2). 30 May 2000.	-
	31.	Xie, M., et al GenBank Accession Number AF279437 for Homo sapiens interleukin 22 (IL22). 09 Oct 2000.	
	32.	Dumoutier, L., et al. GenBank Accession Number AJ294727 for Mus musculus ILTIFa gene for IL TIE aipna	_
==3	33.	Dumoutier, L., et al. GenBank Accession Number NP_065386 for Interleukin 22; interleukin 21; IL-10-related T-cell-derived inducible factor (homo sapiens). 02 Nov 2000.	
	34.	Ozaki, T., et al., "Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictrostellium discoideum." Development, 117(4):1299-308, 1993.	
	35.	Sambrook, J., et al. Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press,	
		1989, Ch. 17.	
	36.	Xie, M.H., et al., "Interleukin IL-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R," J. Biol. Chem. 275(40):31335-9, 2000.	

S:\LACOMMON\PATENTS\AMEND\5358\CIP\PTO 1449.doc

Examiner	Date
Signature	Considered